Brighton Jones LLC Raises Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Brighton Jones LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.5% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 920 shares of the biopharmaceutical company’s stock after buying an additional 14 shares during the period. Brighton Jones LLC’s holdings in Regeneron Pharmaceuticals were worth $967,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Sachetta LLC raised its stake in Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 10 shares during the last quarter. Stephens Consulting LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $26,000. West Paces Advisors Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 575.0% during the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 23 shares during the period. Crewe Advisors LLC purchased a new position in Regeneron Pharmaceuticals in the 1st quarter valued at $28,000. Finally, Lynx Investment Advisory acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at $33,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Down 0.4 %

REGN stock opened at $1,145.03 on Friday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The company’s 50 day simple moving average is $1,131.75 and its 200-day simple moving average is $1,031.74. Regeneron Pharmaceuticals, Inc. has a 12 month low of $769.19 and a 12 month high of $1,211.20. The firm has a market capitalization of $126.17 billion, a PE ratio of 33.83, a P/E/G ratio of 3.93 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.38 billion. During the same quarter in the prior year, the firm earned $8.79 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 12.3% on a year-over-year basis. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

REGN has been the topic of several analyst reports. TD Cowen lifted their target price on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. Wells Fargo & Company increased their target price on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. StockNews.com upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, September 10th. Finally, Argus upped their price objective on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $1,111.30.

Insider Activity at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the sale, the vice president now owns 4,204 shares in the company, valued at $4,498,280. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The disclosure for this sale can be found here. Insiders have sold a total of 10,026 shares of company stock valued at $11,498,705 over the last quarter. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.